The impact of the revised ESC Dyslipidaemia Guidelines on lipid-lowering therapy: simulating the need for PCSK9 inhibition in a contemporary ASCVD cohort

29 August 2020 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Risk Factors and Prevention ePosters Drug therapy ESC Premium Access ESC Congress 2020

ESC 365 is supported by

ESC 365 is supported by